Company intelligence / Profile preview

AnchorDx

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Commercial

Overview

AnchorDx has developed and commercialized early detection products using ctDNA high-throughput methylation sequencing. Their tests cover over 70% of high-incidence cancers. The company has a proprietary genome database focused on early-stage molecular signatures and an AI platform for lung cancer screening. They have filed numerous patents in molecular biology and oncology. No traditional clinical trial results as the focus is on diagnostics.

Therapeutic areas: Oncology
Modalities: Liquid biopsy diagnostics (ctDNA-based)DNA methylation sequencing technology
Industry: Molecular Diagnostics

Drug pipeline

2 assets

PulmoSeek

Commercial

Indications: Lung cancer

1 more asset in the full pipeline.

Request access →

Partnerships

DiaCarta – partnership to co-develop global molecular diagnostic products for early cancer screening

Beyond the preview

Go deeper on AnchorDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnchorDx.

Explore the full profile